EyePoint (EYPT) CMO exercises options, then sells 42,544 shares of stock

Rhea-AI Filing Summary

EyePoint, Inc. Chief Medical Officer Ribeiro Ramiro reported exercising stock options and selling company shares. On January 5, 2026, Ramiro exercised an option to buy 29,250 shares of common stock at $8.26 per share, increasing his directly held common stock to 42,544 shares. That same day, he reported selling 42,544 shares of common stock at a weighted average price of $17.0957 per share, leaving him with no directly held common stock after the transactions.

Ramiro continues to hold 87,750 stock options following the reported activity. According to the filing, the option vests with 25% on January 3, 2026, with the remaining portion vesting monthly over the next three years, and carries an expiration date of January 3, 2035. The weighted average sale price reflects multiple trades between $16.68 and $17.51.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ribeiro Ramiro

(Last) (First) (Middle)

C/O EYEPOINT, INC

480 PLEASANT STREET, SUITE C400

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EyePoint, Inc. [ EYPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		M		29,250	A	$8.26	42,544	D
Common Stock	01/05/2026		S		42,544	D	$17.0957(1)	0.00	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.26	01/05/2026		M			29,250	(2)	01/03/2035	Common Stock	29,250	$0.00	87,750	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.68 to $17.51. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

Remarks:

	/s/ Ron Honig, Attorney-in-Fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did EyePoint (EYPT) report for the Chief Medical Officer?

EyePoint, Inc. reported that Chief Medical Officer Ribeiro Ramiro exercised stock options for 29,250 shares of common stock at $8.26 per share and on the same day sold 42,544 shares of common stock at a weighted average price of $17.0957 per share, resulting in no directly held common stock after the sale.

How many EyePoint (EYPT) shares did the CMO sell and at what price?

The Chief Medical Officer reported selling 42,544 shares of EyePoint common stock at a weighted average price of $17.0957 per share, with individual trades occurring between $16.68 and $17.51.

How many EyePoint (EYPT) stock options does the CMO hold after the reported transactions?

Following the transactions, the Chief Medical Officer beneficially owns 87,750 stock options (right to buy common stock), as reported in the filing.

What is the exercise price and expiration date of the CMO’s EyePoint (EYPT) stock options?

The reported stock option has an exercise price of $8.26 per share and an expiration date of January 3, 2035, according to the derivative securities table.

How do the EyePoint (EYPT) stock options held by the CMO vest?

Per the footnote, the option vests and becomes exercisable with 25% vesting on January 3, 2026, and the remainder vesting ratably on a monthly basis over the following three years.

Does the EyePoint (EYPT) filing explain the weighted average sale price?

Yes. A footnote states the $17.0957 price is a weighted average, and that the shares were sold in multiple transactions between $16.68 and $17.51. The reporting person undertakes to provide full trade detail upon request.